@entity3446 for the treatment of noninfectious XXXX .

@entity1596 @entity1939 @entity3446 @entity23351 @entity288
INTRODUCTION: @entity23351 ( @entity23351 ) remains a significant burden of @entity1939 . Because of its immune mediated and chronic recurrent nature, common therapy includes (systemic) @entity288 and immune modulatory agents. Most treatments bear the risk of significant adverse effects. Therefore efforts are made to administer therapeutic agents directly into the vitreous cavity. The purpose of this article is to identify the role of intravitreally applied @entity3446 as a recently approved therapeutic option in @entity23351 . Areas covered: A MEDLINE database search was conducted through August 2015 using the terms: intravitreal injection, pharmacology, @entity3446 , treatment, and @entity1596 . To provide ongoing and future perspectives in treatment options, also clinical trials as registered at ClinicalTrials.gov were included. @entity3446 (Opsiria) was in licensed from SANTEN in 2015 and approved in Phase III registration trials in the U.S., Europe and other countries for @entity23351 . Current information results mainly from registration and phase III trials. Expert opinion: Intravitreal @entity3446 appears to be an interesting option in the treatment algorithms of @entity23351 because of its highly targeted molecular effects, nonsteroidal nature and good safety profile. It has the advantage to avoid systemic side effects, but this has to be balanced against the fact that treatment covers one eye only and bears the risks of any intraocular procedure. Nevertheless a careful evaluation of this agent has to be made, since current experience is almost exclusively based on registration trials, and long term effects still have to be explored.
